These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38242326)

  • 1. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
    Espinoza AF; Patel RH; Patel KR; Badachhape AA; Whitlock R; Srivastava RK; Govindu SR; Duong A; Kona A; Kureti P; Armbruster B; Kats D; Srinivasan RR; Dobrolecki LE; Yu X; Najaf Panah MJ; Zorman B; Sarabia SF; Urbicain M; Major A; Bissig KD; Keller C; Lewis MT; Heczey A; Sumazin P; López-Terrada DH; Woodfield SE; Vasudevan SA
    J Hepatol; 2024 Apr; 80(4):610-621. PubMed ID: 38242326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
    Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
    Lachenmayer A; Toffanin S; Cabellos L; Alsinet C; Hoshida Y; Villanueva A; Minguez B; Tsai HW; Ward SC; Thung S; Friedman SL; Llovet JM
    J Hepatol; 2012 Jun; 56(6):1343-50. PubMed ID: 22322234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
    Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
    Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
    Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
    Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
    Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
    Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
    JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
    Berdeja JG; Laubach JP; Richter J; Stricker S; Spencer A; Richardson PG; Chari A
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):752-765. PubMed ID: 34340951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    Sato A; Asano T; Isono M; Ito K; Asano T
    BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines.
    Lopes N; Salta S; Flores BT; Miranda-Gonçalves V; Correia MP; Gigliano D; Guimarães R; Henrique R; Jerónimo C
    Clin Epigenetics; 2024 Aug; 16(1):102. PubMed ID: 39097736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
    Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
    Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
    Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
    PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
    Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
    Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deacetylase inhibitors: an advance in myeloma therapy?
    Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
    Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.